One in Three Individuals in the U.S. has Some Form of Cardiovascular Disease
Stern Cardiovascular Foundation announced that it is actively recruiting individuals with a prior history of heart attack, stroke or related cardiovascular events to participate in a clinical research study called Fourier.
The Fourier Study, sponsored by Amgen, is a clinical research study to find out if an investigational medication may reduce the risk of future heart attacks, strokes, related cardiovascular events and death in individuals with a prior history of these conditions. The study is investigating a different approach to reducing LDL cholesterol or “bad” cholesterol.
Hypercholesterolemia, or high cholesterol, is a major public health issue in most countries as it contributes to the risk of developing cardiovascular disease, the leading cause of death among men and women (2). According to the Centers for Disease Control and Prevention, more than 71 million American adults (33.5%) have high LDL or “bad” cholesterol and only one out of every three adults with high LDL cholesterol has the condition under control (3).
“Cardiovascular disease claims more lives each year than cancer, chronic lower respiratory disease and accidents combined,” said Frank McGrew, M.D., principal investigator for the study at Stern Cardiovascular Foundation. “Through this study we hope to advance our knowledge of cardiovascular disease.”
If you are 40-85 years of age and have had a heart attack, stroke or peripheral artery disease, you may be eligible to participate in The Fourier Study. Participants will receive study required medical care and may receive study medication. Participants may also receive compensation for time and travel.
Learn more by calling 901-271-4065 or visiting www.heartclinicalstudy.com